Fallah J, Zhang L, Amatya A, et al. - The efficacy and safety of second-generation androgen receptor inhibitors were investigated in men aged 80 years or older with non-metastatic castration-resistant prostate cancer. Researchers performed this pooled analysis including 4,117 patients who were assigned to receive androgen receptor inhibitor (apalutamide, enzalutamide, or daralutamide; n = 2,694) or placebo (n = 1,423) across three randomized trials. Based on outcomes, androgen receptor inhibitors were supported to have utility in older men with non-metastatic castration-resistant prostate cancer. Researchers suggest a possible benefit of incorporating geriatric assessment tools in the care of older adults with non-metastatic castration-resistant prostate cancer for offering individualized treatment to each patient.